Starting on 4/12 and lasting until 4/20, High Profile will be offering big discounts on top of everyday low prices on their wide selection.

The post Escape to paradise this 420 with High Profile appeared first on Leafly.

The post Escape to paradise this 420 with High Profile appeared first on Paradise Found.

Including New Mexico’s biggest medical shop.

The post New weed shops of America: Miami’s first, New Mexico’s biggest, and Puerto Rico’s Cush appeared first on Leafly.

The post New weed shops of America: Miami’s first, New Mexico’s biggest, and Puerto Rico’s Cush appeared first on Paradise Found.

Including the Depp South’s biggest medical shop.

The post America’s cannabis dispensary grand openings for January 2025 appeared first on Leafly.

The post America’s cannabis dispensary grand openings for January 2025 appeared first on Paradise Found.

At least 10 states and Amsterdam have new stores for you.

The post Grand Openings: Wu-Tang Clan opens shop in New Jersey appeared first on Leafly.

The post Grand Openings: Wu-Tang Clan opens shop in New Jersey appeared first on Paradise Found.

Cannabis each day keeps prostate cancer away: Prostate cancer (PC) prevalence was lower in both current and former cannabis users compared to non-users in a recent study.

Alternative medicines are needed. In the United States, one in eight men will be diagnosed with prostate cancer in his lifetime—the most common non-skin cancer form. For this reason, men are encouraged to get screened for PC before it’s too late.

The study, “Marijuana Use May Be Associated with Reduced Prevalence of Prostate Cancer: A National Survey on Drug Use and Health Study from United States of America,” was published in the May 2024 issue of Biomedicines. The research was conducted by co-authors Turab Mohammed, James Yu, Yong Qiao, Youngchul Kim, Eric Mortensen, Helen Swede, Zhao Wu, Jingsong Zhang.

NORML reports that researchers affiliated with the University of Connecticut School of Medicine and the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida assessed the relationship between cannabis consumption and PC.

The study represents a nationally representative cohort of 2,503 participants. Investigators reported that subjects between the ages of 50 and 64 who identified as either current or former cannabis consumers possessed a significantly lower risk of prostate cancer diagnoses. 

For the data, researchers undertook a cross-sectional study using National Survey on Drug Use and Health data from 2002 to 2020. The independent variable was cannabis use status (current, former, never), while the dependent variable was self-reported PC (yes, no). 

The anticancer effects of cannabis have been explored for some time. Scientists suggested that this finding provides “biological support for the anti-cancer effects of the constituents of marijuana.” Numerous preclinical trials have documented the ability of cannabinoids to inhibit cancer cell growth. 

Researchers noted that PC prevalence was significantly lower in cannabis users and former uses compared to non-users.

“PC prevalence was lower among current marijuana users (46/145, 31.7%) and former users (323/1021, 31.6%) compared to non-users (534/1337, 39.9%, p < 0.001),” the report reads. “PC prevalence was lower among users versus non-users in the elderly (≥65) (36.4% vs. 42.4%, p = 0.016) and non-Hispanic white subgroups (28.9% vs. 38.3%, p < 0.001). There were no significant PC prevalence differences between users and non-users in the younger population (50-64) or other race/ethnicity. In the multivariable analyses, former marijuana use was associated with lower PC compared to never using (odd ratio = 0.74, 95% CI 0.62-0.90, p = 0.001). Current use was also suggestive of reduced prevalence but was not statistically significant (odd ratio = 0.77, 95% CI 0.52-1.14, p = 0.198), possibly due to low sample size. Our findings from a large national survey provide additional data to link marijuana use with lower PC prevalence.”

Over the course of the case study, the woman reported minor setbacks. But by the end of 2022, the woman reported a “complete resolution of her symptoms” and she went back to full-time work.

Cannabis’s Potential in Cancer Treatment

The National Institutes of Health (NIH) announced grant funds in 2022 to researchers who are studying cannabis treatment for cancer.

A “Notice of Special Interest” (NOSI) (entitled “Basic Mechanisms of Cannabis and Cannabinoid Action in Cancer”) was posted on May 5 by NIH’s National Cancer Institute, with the intent “to promote research in understanding the mechanisms by which cannabis and cannabinoids affect cancer biology, cancer interception, cancer treatment and resistance, and management of cancer symptoms.”

In the notice, NIH explains that the reasoning behind this effort is due to the growing number of cancer patients seeking relief with medical cannabis, but that there are not enough studies to verify its effectiveness. “Cancer patients use cannabis and cannabinoids to manage symptoms of cancer and cancer treatment including anorexia, nausea, and pain,” the NOSI states. “Recent survey evidence suggests that a quarter of cancer patients have used cannabis for symptom management. Despite the increase in cannabis and cannabinoid use, research about their health effects, including potential harms and benefits, remain limited.” 

The report also briefly defines the activity of various cannabinoid receptors in the human body through animal models and cancer cell lines. “Cancer cell line experiments show that THC and CBD can mediate many anti-tumor effects, including inducing apoptosis and inhibiting cell proliferation, invasion, and angiogenesis,” the NOSI states. “These anti-tumor activities have led to early clinical testing of THC and CBD for glioblastoma and prostate cancers. While preclinical studies show differing effects of cannabinoids on cancer cells, deeper understanding is needed about how the tumor promoting and suppressive mechanisms of cannabinoid signaling influence cancer biological processes.”

The new report sheds light on specific cancer types that cannabis could play a role in, namely prostate cancer.

The post Cannabis Use Linked to Lower Rates of Prostate Cancer, Study Shows first appeared on High Times.

The post Cannabis Use Linked to Lower Rates of Prostate Cancer, Study Shows appeared first on Paradise Found.

A pilot program on the benefits of synthetic psilocybin for mental health issues like post-traumatic stress disorder (PTSD) is set to begin this summer at Yale University in New Haven, Connecticut. 

A study cohort will consist of 50 patients, mostly veterans and first responders, who are with mental health concerns like depression and addiction. Participants will take 25 mg of synthetic psilocybin, and after the psychedelic effects wind down, they will discuss issues and progress (or lack thereof) with trained therapists.

Connecticut Post reports that the goal is to fulfill the need for state data that has been lacking, according to state Rep. Michelle Cook (D-Torrington).

“We need to have the data to show that there is documented proof of what that therapy does,” Cook said. “We know that it has some incredible outcomes when it is done right, when it’s done by people that are trained in how to use it for treatment of PTSD and so forth.”

Researchers at Yale have been studying the “psychological, neurobiological, and therapeutic effects of psychedelic substances” like psilocybin for decades..

Using a Schedule 1 drug in a clinical setting creates a set of unique problems, including the inability to use insurance. “Even though it’s a research program, you are treating them clinically. And then, in order to treat them clinically, you need to have malpractice coverage,” said Yale researcher Ben Kelmendi. Kelmendi and his team are about to embark on a first-of-its-kind study, a pilot program at Yale.

Research on the medical benefits of  psilocybin have been severely hampered due to legal restrictions, Kelmendi said. Only certain qualifying conditions are acceptable in this case. PTSD, for instance, is a complex issue that many people fail to treat.

“With veterans, they will not seek treatment right away,” Kelmendi said. “They will start turning to alcohol or other substances, and so that now they have a comorbidity, and that comorbidity—which really is their own way of coping—will exclude them from the study. They are real patients who are actually suffering and who actually need help. They cannot access these medicines because they do not fit that cookie-cutter profile.” 

The impact of PTSD is hard to define as it affects multiple aspects of daily life.

“There is no one scale that actually captures the complexity of one’s daily functional impairment. It’s actually an index of several different scales,” he said. “One is days missed at work, productivity and relationships, just more daily living. I think that is much more important than saying ‘Oh, have your PTSD symptoms improved or not?’”

Participants will take 25 mg of synthetic psilocybin, enough to induce a psychedelic experience, and the therapy is patient-directed. They will be taken in a comfortable space and about six hours later, participants will undergo a psychotherapy session. 

“Twenty-five milligrams would be considered a moderate dose. It’s not a heroic dose necessarily, but it’s a psychoactive dose, for sure,” Kelmendi said. “The non-directive supportive psychotherapy is to be done after the dosing rather than during the dosing.”

The Many Potential Health Benefits of Psilocybin 

The Yale Program for Psychedelic Science supports this goal with several currently active studies on psilocybin. These include studies on Obsessive Compulsive Disorder (OCD), Major Depressive Disorder (MDD), cluster headaches, post-traumatic headaches, and migraines. Kelmendi is working on several of them.A 2022 report published by a working group under the direction of the Connecticut Department of Mental Health and Addiction Services, was clear about the potential of psilocybin in therapeutic medicine. 

Even people who don’t necessarily intend to gain benefits for mental health from psilocybin are still benefitting, a separate study suggests. A study published last September found that using psilocybin outside of a clinical setting was associated with mental health benefits including decreases in anxiety and depression. The research, which was published September in the journal Frontiers in Psychiatry, studied nearly 3,000 people who reported on their experience taking psilocybin mushrooms. 

To conduct the study, which is reportedly the largest study of psilocybin in a naturalistic (non-clinical) setting, researchers spent two years collecting data from 2,833 participants who planned to take psilocybin for purposes of “self-exploration.” Most participants were college-educated white men in the United States who had previous experience taking psychedelic drugs.

The study participants were asked to fill out five surveys as part of the research. The first survey was completed two weeks prior to the psilocybin experience, which usually consisted of ingesting dried mushrooms, and again the day before the planned psychedelic trip. The remaining surveys were taken one to three days after the experience, two to four weeks after and two to four months after taking the psilocybin. 

After analyzing the data from the surveys, researchers determined that participants reported long-lasting reductions in anxiety, depression, alcohol misuse, neuroticism and burnout. Additionally, the participants reported improvements in cognitive flexibility, emotion regulation, spiritual well-being and extraversion. The new research aims to add to the body of knowledge of what is known about the effects of psilocybin.

The post Yale Researchers To Study Psilocybin for PTSD, Mental Conditions first appeared on High Times.

The post Yale Researchers To Study Psilocybin for PTSD, Mental Conditions appeared first on Paradise Found.

Gifting parties—events that allow guests to buy a random item that includes a cannabis “gift”—will be subject to strict rules after Connecticut’s attorney general arrived at an agreement with organizers of one such event that attracted attention of state officials.

Attorney General William Tong announced May 15 that he reached an agreement, with stipulations, that HighBazaar organizers Joseph Accettullo and Cody Roberts can continue running gifting parties, however, the parties will not resemble what they used to be.

For $20 per ticket, attendees could gain entry to the event to buy accessories or other items and receive cannabis “gifts” on the side in an attempt to cut corners—namely, avoiding the law requiring sellers to have a license. Connecticut banned cannabis gifting events in 2022.

Tong alleged that HighBazaar events were essentially cannabis marketplaces that subverted Connecticut’s legal, regulated cannabis market. HighBazaar’s gifting events were canceled last January after Tong issued cease-and-desist orders in a letter to organizers and the venue.  

“It appears that these events involve the illegal marketing and sale of cannabis outside of the regulated market and that the events are accessible to individuals under the age of 21,” the letter read. Tong warned that the markets appeared to violate the Connecticut Unfair Trade Practices Act (“CUTPA”), General Statutes § 42-110a, et seq., the Responsible and Equitable Regulation of Adult-Use Cannabis Act, General Statutes § 21a-420, and/or other applicable laws and regulations. But Tong reached an agreement with HighBazaar that will allow them to continue to operate with several restrictions.

“HighBazaar operated unlawful cannabis markets where vendors peddled untested, illegal products. Not anymore. This stipulated judgment forces a series of strong, ongoing obligations, including clear and conspicuous disclosures and acknowledgements that the sale, distribution and exchange of cannabis will be strictly prohibited at any HighBazaar event. We will be watching closely—including unannounced inspections—to ensure strict, ongoing compliance,” said Attorney General William Tong.

The stipulations include that Accettullo and Roberts must make clear and conspicuous disclosures at HighBazaar events and on any advertisements that the sale, distribution, or exchange of cannabis will be strictly prohibited. 

All prospective vendors must be notified in advance, and must acknowledge in writing that they will not sell, offer, distribute, or exchange cannabis at any HighBazaar event. judgment provides the Office of the Attorney General the right to enter and inspect HighBazaar premises at any time to ensure compliance with the agreement.

CT Insider reports that Alex Taubes, an attorney for HighBazaar organizers, called the judgment a “great victory” and said he was “pleased that the state finally saw some reason.”

The Office of the Attorney General also previously sent notice to EventBrite, where HighBazaar was promoting its gifting events. The letter warned that such posts violate EventBrite’s own Community Guidelines and that the events they promoted also violate Connecticut law. The Office of the Attorney General has an active and ongoing investigation into EventBrite’s continued marketing of unlicensed cannabis markets in Connecticut.

Assistant Attorneys General Jonathan Blake and Addison Keilty, and Deputy Associate Attorney General Michael Wertheimer, Chief of the Consumer Protection Section, assisted the Attorney General in this matter.

Cannabis Legal Loopholes in Connecticut

Another legal loophole in Connecticut led to THC-infused seltzers surging in popularity.

Liquor stores in Connecticut are selling THC-infused drinks such as seltzers legally, due to a legal loophole regarding dosages listed on the cans.

Cannabis retail stores are selling cans listed as one serving, but the same cans of cannabis-infused seltzer, usually running in sizes from 7.5 – 12 ounces, are labeled as five servings in a package at a liquor store or market.

All they have to do is ensure that each serving contains less than 1 mg of THC per serving and they can sell the seltzers without violating state law. CT Insider reports that when the drinks are labeled as five servings rather than one, they are technically legal to be sold anywhere in the state, so long as other elements of the packaging are in line with state rules.

Connecticut’s Department of Consumer Protection (DCP) clarified that the drinks are indeed legal. “A package containing less than 1 milligram of THC per serving and less than 5 milligram per package is not considered cannabis, and may be produced and sold without a license,” DCP spokesperson Kaitlyn Krasselt confirmed. 

Connecticut legalized adult-use cannabis in 2021 and later became available for purchase by adults at retail outlets in January 2023. Connecticut Gov. Ned Lamont signed legislation to legalize adult-use cannabis in June 2021, ending the prohibition on possession of cannabis by adults 21 and older and creating a framework for regulated adult-use cannabis sales. Connecticut’s cannabis market showed steady growth

The post Gifting Parties in Connecticut Can Continue with Limits Under Settlement with Attorney General first appeared on High Times.

The post Gifting Parties in Connecticut Can Continue with Limits Under Settlement with Attorney General appeared first on Paradise Found.

The Connecticut House of Representatives this week passed a bill to regulate ingestible hemp products, with lawmakers saying the legislation is necessary to protect the public from the potentially harmful effects of hemp-derived cannabinoids. The House approved the measure, House Bill 5150, by a vote of 130-16 on Tuesday, less than three months after it was introduced in the legislature by the House General Law Committee. The legislation now heads to the Connecticut Senate for consideration.

Hemp agriculture and products made from hemp were legalized more than five years ago with the passage of the 2018 Farm Bill by the U.S. Congress. Since then, a multitude of ingestible hemp products, many with intoxicating cannabinoids, have been introduced to the market, with widespread availability at retailers including convenience stores, gas stations and smoke shops. Representative Mike D’Agostino, one of the lead sponsors of the bill, said that legislation is needed to put controls on the unregulated market for hemp-derived cannabinoid products.

“We can’t ban them, but we can regulate the hell out of them,” said Democratic Representative Mike D’Agostino, the co-chair of the General Law Committee, according to a report from the Hartford Courant. “We say, OK, those products need to be manufactured in accordance with our standards. They need to be labeled in accordance with our standards they have to be to have disclosures in accordance with our standards.”

The legislation would regulate hemp products including THC-infused beverages, limiting the sale of certain products to adults age 21 and older. The bill also redefines and expands the definition of high-THC hemp products, which are more tightly regulated than others. Additionally, the bill establishes a new category of THC “which it classifies as an ‘infused beverage’ and requires it to meet many of the requirements for manufacturers of hemp products,” according to an Office of Legislative Research report cited by CT News Junkie.

Bill Sets THC Potency Limit

The legislation sets a uniform potency limit for hemp-derived products of one milligram of THC per serving. Products with more THC per serving than the limit would be classified as high-THC products, which would only be available at medical marijuana dispensaries or licensed cannabis retailers, which were established following the legalization of recreational marijuana in Connecticut in 2021. 

The bill also defines unregulated sales of cannabis and hemp products as violations of the Connecticut Unfair Trade Practices Act, a change that makes it easier for the Connecticut Department of Consumer Protection and the attorney general to take unauthorized products off the market.

“We need to make sure that the rules are being followed, that there’s not a product out there that is unregulated, that is being sold to minors, that is being sold in convenience stores, that is outside of the strict structures that we created,” D’Agostino said.

The legislation includes “provisions that allow towns to now go to court and seek to shutter the doors of these vape shops that are selling cannabis or other stores that are selling illegal cannabis, and the towns can get a piece of the revenue and fines that can be levied with respect to that enforcement,” according to the D’Agostino.

“If you’re a town that’s approved legal cannabis, the last thing you want is next door a vape shop that’s selling a competing illegal product,” he added.

The hemp product regulation bill also sets standards for the labeling of hemp products and amends some rules governing the cultivation of cannabis by social equity licensees. D’Agostino noted that the laws and regulations governing cannabis products and sales will continue to evolve, just as they have for other regulated products.

“The liquor laws have been evolving over time for decades since Prohibition ended. We’re three years into this process,” D’Agostino said. “I’ve said it before, I’ll say it again: We’re going to keep coming back and back in this chamber with respect to our cannabis laws and how they evolve and how we respond to that marketplace and make sure we remain in control of it.”

State Representative Dave Rutigliano of Trumbull, the ranking Republican on the General Law Committee, is one of many GOP lawmakers who opposed the legalization of marijuana in Connecticut but voted in favor of the hemp products regulation bill.

“It’s already legal. We can’t make it unlegal. So what we’ve decided to do is try to regulate it in a way that makes a safer environment for everyone,” Rutigliano said. “Our goal this year, as it was last year, is to get THC products, intoxicating products out of our supermarkets, convenience stores and gas stations, to put it in a place where it’s regulated, where it’s taxed and controlled.”

The post Connecticut House Approves Bill Regulating Hemp Products first appeared on High Times.

The post Connecticut House Approves Bill Regulating Hemp Products appeared first on Paradise Found.

Connecticut’s Department of Consumer Protection (DCP) published a new dataset, showing the price per gram of “usable cannabis” sold in the state’s adult-use cannabis and medical marijuana markets, according to a March 11 press release. 

The dataset’s category “usable cannabis” essentially means flower and includes raw flower in whole, ground, or pre-rolled form, without additional extracted materials.

Currently, a gram of cannabis in California is hovering around $12 per gram, which is slightly up from years prior. The Register Citizen reports that the average price per gram of cannabis in Connecticut has increased steadily for months since October 2023, when the cost of cannabis was at $9.68 per gram—its lowest since adult-use sales kicked off in the state. The price of flower in Connecticut has increased, going from an average of $11.93 per gram in January to $12.28 per gram in February. 

“In February, the average price per gram of usable cannabis was $12.28,” the announcement reads. “The new dataset includes data collected since the market opened in January 2023.”

According to High Times Trans-High Market Quotations in the March issue, which does not track the price per gram, the average price of an ounce across America was $296. This means that when you’re buying in bulk, the average price per gram dips to around $10.

The state recorded $15.6 million in adult-use cannabis sales during the month of February, plus an additional $9.4 million in medical cannabis sales, for a total of $25 million in total cannabis sales, state data shows. It represents a $2.6 million decrease in total cannabis sales from January, when sales were down $2.6 million from the previous month. 

The dataset was added as part of the Department’s monthly data release, which to date has included total retail sales, number of products sold, average product price, and types of products sold. The most recent data for each dataset have also been published in accordance with the Department’s monthly cannabis data schedule.

The data will continue to be updated monthly on or after the 10th of each month. Going forward, DCP will make announcements when new datasets have been made publicly available, and the DCP will no longer issue monthly press releases related to existing datasets.

Reporters and members of the public who are interested in new monthly data published to existing datasets should check ct.gov/cannabis monthly on the 10th or the first business day after the 10th of each month.

The data does not include taxes collected at the point of sale on adult-use transactions, and medical cannabis patients do not pay taxes.

Connecticut Doubles Limit on Cannabis Purchases

Last November, Connecticut regulators doubled the amount of adult-use cannabis consumers can purchase in a single transaction.

Connecticut’s cannabis regulatory agency announced an increase in the amount of cannabis that can be bought in a single transaction by doubling the state’s limit on recreational marijuana purchases. Under the new regulations approved by the DCP, adult-use cannabis consumers are permitted to purchase up to a half-ounce (about 14 grams) of cannabis flower or its equivalent beginning next month. 

The limit on purchases of medical marijuana has not been changed. It remains at 5 ounces of cannabis flower or the equivalent monthly, with no limits on purchases in a single transaction.

“DCP has continually reviewed available supply and demand since prior to the launch of the adult-use cannabis industry in January 2023,” DCP Commissioner Bryan T. Cafferelli said in a statement from the agency. “As more retailers, production companies and other supply chain licensees have come online, the capacity of the industry has increased. We are confident this measured approach to adult-use sales has resulted in a healthy market for businesses, and a safe and fair marketplace for adult-use cannabis consumers and medical marijuana patients.”

Connecticut collects data through BioTrack, the state’s Seed-to-Sale Tracking System, a real-time inventory system used to track an individual cannabis plant from the point it is planted as a seed or clone to the point of sale.

All medical and adult-use cannabis licensees are required to input data into this system, showing the movement of cannabis products as they are grown, manufactured, tested, and ultimately sold. (Information about the person who purchases the final cannabis product is not recorded.) 

Connecticut officials record cannabis sales data every month, so you can map the steady march of adult-use cannabis sales by looking at month-to-month sales on one of their many graphics.

DCP does not make revenue projections, set sales expectations, collect taxes, nor do they regulate prices. The DCP also provides information to protect consumers from common scams and other threats.

The post Connecticut To Show Price Per Gram of Flower Online appeared first on High Times.

The post Connecticut To Show Price Per Gram of Flower Online appeared first on Paradise Found.

Four states—Ohio, Illinois, New Mexico, and Connecticut—are now looking into adding female orgasmic disorder (FOD) to the list of qualifying conditions for medical cannabis. There’s mounting research that suggests that cannabis can help women have more orgasms. For those with FOD, defined by the Merck Manuel as a “lack of or delay in sexual climax (orgasm) or orgasm that is infrequent or much less intense even though sexual stimulation is sufficient and the woman is sexually aroused mentally and emotionally,” medical marijuana could not only make having an orgasm easier, but more satisfying. 

Diagnosis criteria and scientific research aside, stoners have been boasting about the sexual properties of cannabis, probably since the herb was first smoked. Now, we know that cannabis, as a vasodilator, can increase blood flow to the genitals. Because it can also aid in anxiety, using some weed before sex can help people relax into the moment, which can be especially beneficial to those whose sexual dysfunction stems from trauma. After all, we know that cannabis has a well-documented ability to treat PTSD. It even enhances the senses, often making touching and even checking out your partner more fun. And as cannabis can also aid in creativity, it can help you consider and explore more variations in your sex life. 

“Women with FOD have more mental health issues, are on more pharmaceutical medication,” Suzanne Mulvehill, clinical sexologist, and founder and executive director of the nonprofit Female Orgasm Research Institute told Marijuana Moment. “They have more anxiety, depression, PTSD, more sexual abuse histories. It’s not just about pleasure, it’s about a human right,” adding that: “It’s a medical condition that deserves medical treatment.”

Ohio is currently evaluating a proposed amendment to add the condition. Earlier this month, the State Medical Board declared that both FOD and autism spectrum disorder are advancing to the stages of expert assessment and public feedback, following online petition submissions. Public comments will be accepted until Thursday.

In Illinois, regulatory officials are scheduled for a meeting next month to discuss the inclusion of FOD as an eligible condition. New Mexico plans to address the matter in May, as per the nonprofit Female Orgasm Research Institute. The organization also noted that Connecticut is exploring the possibility of adding FOD to its list of qualifying conditions, although a specific date for a meeting has not yet been determined.

Suzanne Mulvehill plays a leading role in the initiatives advancing the therapeutic advantages of cannabis for individuals with FOD. She says that this condition impacts as many as 41% of women globally. She filed a petition last year aiming to include this disorder among Ohio’s list of conditions eligible for medical marijuana.

Present studies suggest that approximately one-third of women who consume cannabis utilize it to enhance sexual experiences—a statistic Mulvehill notes has remained relatively consistent over the years.

She’s aware of the understanding surrounding cannabis’s ability to enhance sex. “It’s not new information,” Mulvehill said in her interview with Marijuana Moment. 

The novelty lies in the readiness of government bodies to address the matter. According to Mulvehill, Ohio appears to be the first state to evaluate FOD as a condition warranting medical marijuana. Moreover, she noted that Ohio’s meeting earlier in the month marked the inaugural instance, to her knowledge, of a public government entity discussing female orgasmic disorders.

A 2020 article published in Sexual Medicine discovered that frequent cannabis use among women correlates with improved sexual experiences. Additionally, various online polls have highlighted a positive correlation between cannabis consumption and sexual satisfaction. There’s even research indicating that the enactment of marijuana legislation correlates with a rise in sexual activity.

And research published last year in the Journal of Cannabis Research revealed that over 70% of adults surveyed reported an increase in sexual desire and enhanced orgasms when using cannabis before intercourse, and 62.5% noted improved pleasure during masturbation with cannabis use. Given previous data showing that women who have sex with men often experience orgasms less frequently than their male counterparts, the researchers suggested that cannabis might help bridge this orgasm equality gap.

For some people, having an orgasm is a challenge in a way that counts as a disorder that deserves treatment, and access to medical marijuana is paramount. For others, this new legal push is just a reminder that weed can make sex better and a reminder that you don’t need a diagnosis to have hot, stoned sex.

The post Female Orgasmic Disorder Could Become a Qualifying Condition for Medical Cannabis in Four States appeared first on High Times.

The post Female Orgasmic Disorder Could Become a Qualifying Condition for Medical Cannabis in Four States appeared first on Paradise Found.